Asset Management One Co. Ltd. Has $10.41 Million Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Asset Management One Co. Ltd. grew its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 14.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 457,371 shares of the company’s stock after purchasing an additional 58,413 shares during the quarter. Asset Management One Co. Ltd.’s holdings in Teva Pharmaceutical Industries were worth $10,414,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $104,000. Allspring Global Investments Holdings LLC increased its stake in Teva Pharmaceutical Industries by 2,018.3% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,097,096 shares of the company’s stock valued at $23,368,000 after purchasing an additional 1,045,305 shares in the last quarter. Gladstone Institutional Advisory LLC increased its stake in Teva Pharmaceutical Industries by 7.2% in the fourth quarter. Gladstone Institutional Advisory LLC now owns 154,249 shares of the company’s stock valued at $3,400,000 after purchasing an additional 10,310 shares in the last quarter. Kestra Private Wealth Services LLC increased its stake in Teva Pharmaceutical Industries by 201.7% in the fourth quarter. Kestra Private Wealth Services LLC now owns 31,526 shares of the company’s stock valued at $695,000 after purchasing an additional 21,075 shares in the last quarter. Finally, WCM Investment Management LLC increased its position in Teva Pharmaceutical Industries by 125.6% in the 4th quarter. WCM Investment Management LLC now owns 135,754 shares of the company’s stock valued at $3,030,000 after buying an additional 75,584 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now owns 44,104 shares in the company, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Roberto Mignone sold 286,000 shares of the company’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the sale, the director now owns 695,000 shares of the company’s stock, valued at $15,296,950. This represents a 29.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.55% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on TEVA. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. JPMorgan Chase & Co. upped their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. UBS Group decreased their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a report on Thursday, January 30th. Barclays reduced their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. Finally, Piper Sandler upped their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $23.57.

Teva Pharmaceutical Industries Price Performance

TEVA stock opened at $16.24 on Tuesday. The firm has a 50 day moving average of $19.93 and a 200-day moving average of $18.50. The company has a current ratio of 0.98, a quick ratio of 0.61 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a 12 month low of $12.51 and a 12 month high of $22.80. The firm has a market capitalization of $18.39 billion, a P/E ratio of -11.20, a price-to-earnings-growth ratio of 1.39 and a beta of 0.71.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, sell-side analysts predict that Teva Pharmaceutical Industries Limited will post 2.62 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.